NERV Stock Analysis: Buy, Sell, or Hold?
NERV - Minerva Neurosciences, Inc
$4.27
-0.45 (-9.53%)
▼
5d:
-13.21%
30d:
-8.57%
90d:
-22.5%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When NERV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NERV is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NERV is down 13.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NERV is currently trading at $4.27, which is considered oversold relative to its 30-day fair value range of $4.32 to $5.02.
Technical Outlook: Technically, NERV is showing sideways momentum. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+122.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NERV is showing sideways momentum. The price is currently testing key support at $4.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 9.5% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.50 (+122.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.32 -
$5.02
Company Quality Score
54/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BEARISH: Downward momentum (-9.5%)
- BULLISH: Trading 122.5% below Wall St target ($9.50)
- WARNING: Recommendation downgraded due to -13.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$4.32 -
$5.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.45
Resistance Level
$5.49
Current Trend
Sideways
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.37
Wall Street Target
$9.50
(+122.5%)
Share & Embed Analysis
Last updated: July 13, 2026 6:53 PM ET
Data refreshes hourly during market hours. Next update: 7:53 PM
Data refreshes hourly during market hours. Next update: 7:53 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NERV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$413 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
